In particular, the transcriptional levels of CCND2 were significantly lower in prostate tumors than in normal tissues, and the results from one cohort of Chinese32 and other sixteen independent clinical data sets30, 32–47 with a total amount of 1,083 samples showed that CCND2 was markedly underexpressed upon tumor progression to advanced stage and metastasis (Fig. 3a–g and Supplementary Fig. 2a–j). This evidence concerns the gene CCND2 and prostate neoplasm.